Non‐alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver dis‐ ease in clinical practice and, consequently, a major health problem worldwide. It affects approxi‐ mately 30% of adults in the general population and up to 70% of patients with type 2 diabetes (T2DM). Despite the current knowledge of the epidemiology, pathogenesis, and natural history of NAFLD, no specific pharmacological therapies are until now approved for this disease and, con‐ sequently, general strategies have been proposed to manage it. They include: (a) lifestyle change in order to promote weight loss by diet and physical activity, (b) control of the main cardiometabolic risk factors, (c) correction of all modifiable risk factors leading the development and progression of advanced forms of NAFLD, and (d) prevention of hepatic and extra‐hepatic complications. In the last decade, several potential agents have been widely investigated for the treatment of NAFLD and its advanced forms—shedding some light but casting a few shadows. They include some glu‐ cose‐lowering drugs (such as pioglitazone, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, so‐ dium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors), antioxidants (such as vitamin E), statins or other lipid lowering agents, bile and non‐bile acid farnesoid X activated receptor (FXR) agonists, and others. This narrative review discusses in detail the different available approaches with the potential to prevent and treat NAFLD and its advanced forms.

Treatments for NAFLD: State of Art

Alessandro Mantovani
;
Andrea Dalbeni
2021-01-01

Abstract

Non‐alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver dis‐ ease in clinical practice and, consequently, a major health problem worldwide. It affects approxi‐ mately 30% of adults in the general population and up to 70% of patients with type 2 diabetes (T2DM). Despite the current knowledge of the epidemiology, pathogenesis, and natural history of NAFLD, no specific pharmacological therapies are until now approved for this disease and, con‐ sequently, general strategies have been proposed to manage it. They include: (a) lifestyle change in order to promote weight loss by diet and physical activity, (b) control of the main cardiometabolic risk factors, (c) correction of all modifiable risk factors leading the development and progression of advanced forms of NAFLD, and (d) prevention of hepatic and extra‐hepatic complications. In the last decade, several potential agents have been widely investigated for the treatment of NAFLD and its advanced forms—shedding some light but casting a few shadows. They include some glu‐ cose‐lowering drugs (such as pioglitazone, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, so‐ dium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors), antioxidants (such as vitamin E), statins or other lipid lowering agents, bile and non‐bile acid farnesoid X activated receptor (FXR) agonists, and others. This narrative review discusses in detail the different available approaches with the potential to prevent and treat NAFLD and its advanced forms.
2021
NAFLD, MAFLD, nonalcoholic fatty liver disease
File in questo prodotto:
File Dimensione Formato  
Mantovani and Dalbeni_2021_ijms-22-02350.pdf

accesso aperto

Tipologia: Versione dell'editore
Licenza: Dominio pubblico
Dimensione 717.25 kB
Formato Adobe PDF
717.25 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1037749
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 102
  • ???jsp.display-item.citation.isi??? ND
social impact